Drug shows capacity to reduce 'bad' cholesterol levels

Embargoed until: Publicly released: 2025-03-31 05:30

Australia; International; VIC

Photo by jesse orrico on Unsplash

A drug developed to help people at risk of heart disease manage their cholesterol has successfully reduced the levels of a 'bad' cholesterol in study by international and Australian researchers. Drug company Eli Lilly funded a trial of their drug Lepodisiran to investigate how different doses impacted the level of lipoprotein(a), a cholesterol linked to heart disease. 320 people were randomly split into groups which were injected with different doses of Lepodisiran or a placebo. The researchers say the drug was able to lower levels of lipoprotein(a) in the participants' blood and this effect lasted from 60-180 days during the study.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Massachusetts Medical Society, Web page The URL will go live after the embargo ends

Journal/
conference: New England Journal of Medicine

Research:Paper

Organisation/s: Monash University, Cleveland Clinic Coordinating Center for Clinical Research, USA

Funder: Funded by Eli Lilly; ALPACA ClinicalTrials.gov number, NCT05565742.

Media Contact/s

Contact details are only visible to registered journalists.